C5 and paroxysmal nocturnal hemoglobinuria: Novel inhibitors targeting C5 and particularly proximal complement factors have recently emerged, and they are (or will soon be) enlarging the PNH therapeutic armamentarium to improve hemoglobin responses, the control of both residual and breakthrough hemolysis, and/or patients’ quality of life.